Quipt Home Medical (QIPT) Q4 2024 earnings summary

Executive summary

• Achieved record fiscal 2024 revenue of $245.9 million, up 16.2% year-over-year, with adjusted EBITDA of $57.9 million (23.5% margin), and recurring revenue comprising 78% of total revenue.

• Customer base grew to 314,000 unique patients for the year, with 854,000 unique setups/deliveries, up 13% year-over-year; Q4 2024 saw 153,000 unique patients.

• Returned to positive sequential organic growth of 1% in Q4 2024, despite industry headwinds.

• Transitioned to U.S. GAAP reporting in Q4 2024, with prior interim reports restated and bad debt now included in revenue presentation.

• Management anticipates a return to historical organic growth in 2025, supported by demographic trends and a scalable operating model.

Financial highlights

• Fiscal Q4 2024 revenue was $61.3 million, up 3% year-over-year; adjusted EBITDA was $13.4 million (21.8% margin), down 8.8% year-over-year.

• Recurring revenue for 2024 was $190.8 million, or 78% of total revenue, driven by the resupply platform.

• Cash flow from operations was $35.7 million for the year.

• Net leverage ratio at 1.6x; $16.2 million cash on hand and $34.7 million in credit availability.

• Transition from IFRS to GAAP reduced 2023 revenue by $10.1 million, with no impact on Adjusted EBITDA or net loss.

Outlook and guidance

• Expect a return to historical organic growth rates (8%-10%) in calendar 2025 as headwinds subside, supported by strong demand and a robust referral base.

• Guidance for 2025 is 6%-8% free cash flow as a percentage of revenue.

• Positive CPI adjustments for 2025 fee schedules will support organic growth.

• Focus remains on expanding recurring revenue, leveraging technology, and disciplined inorganic growth.